Author’s response to reviews

Title: TRMA syndrome with a severe phenotype, cerebral infarction, and novel compound heterozygous SLC19A2 mutation: a case report

Authors:

Xin Li (Lixin@scmc.com.cn)
Qing Cheng (2011513541@qq.com)
Yu Ding (Dingyu@scmc.com.cn)
Qun Li (15221272316@163.com)
Ruen Yao (yaoruen@scmc.com.cn)
Jian Wang (wangjian@scmc.com.cn)
Xiumin Wang (wangxiumin@scmc.com.cn)

Version: 2 Date: 23 Jun 2019

Author’s response to reviews:

Jun/23/2019

Dear Editor:

Thank you for your letter and your comments concerning our manuscript (ID: BPED-D-19-00266R1). Those comments are all very important for revising and improving our paper. We have studied comments carefully and have made the correction. The revised portion in revised version is marked in red.

Responds to the Editor's comments:

1. We have deleted sections of manuscript which particularly suggest the efficacy and/or advocate for the utilization of the specific treatment according to the comments.

2. We have added the "Declarations" according to the comments.
Special thanks to you for your good comments.

We tried our best to improve the manuscript and made some changes in the manuscript. These changes will not influence the content and framework of the paper. We appreciate for Editors’ warm work earnestly and hope that the correction will meet with approval.

Once again, thank you very much for your comments and suggestions.

Yours sincerely,

Xiumin Wang

Department of Endocrinology and Metabolism, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.

1678 Dongfang Road, Pudong New Area, Shanghai 200127, China.

Tel.: +86 21 38626161;

Fax: +86 21 58393915.

E-mail: wangxiumin@scmc.com.cn